{
    "root": "2f8b2a36-ac60-7762-e063-6294a90ae573",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glycopyrrolate",
    "value": "20250304",
    "ingredients": [
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "GLYCOPYRROLATE",
            "code": "V92SO9WP2I",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00986"
        }
    ],
    "indications": {
        "text": "glycopyrrolate tablets indicated adults reduce symptoms peptic ulcer adjunct treatment peptic ulcer . limitations glycopyrrolate tablets indicated monotherapy treatment peptic ulcer effectiveness peptic ulcer healing established .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "2.1 important dosing information \u2022 glycopyrrolate tablets 2 mg recommended patients lower strength oral glycopyrrolate ( e.g . , glycopyrrolate tablets 1 mg another 1 mg tablet strength ) appropriate initial maintenance treatment strength glycopyrrolate tablets may exceed recommended initial maintenance oral glycopyrrolate tablets . 2.2 recommended \u2022 recommended initial glycopyrrolate tablets 1 mg adults 1 mg three times daily ( morning , early afternoon , bedtime ) . patients may require 2 mg bedtime assure overnight control symptoms . maintenance , 1 mg twice day frequently adequate . \u2022 recommended glycopyrrolate tablets 2 mg adults 2 mg two three times daily equally spaced intervals . \u2022 maximum recommended daily glycopyrrolate 8 mg. \u2022 lowest effective glycopyrrolate control symptoms . patients titrated lower dose , switch glycopyrrolate tablets 2 mg glycopyrrolate tablets 1 mg another 1 mg oral tablet glycopyrrolate .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "glycopyrrolate tablets usp , 1 mg white off-white , round , beveled edge uncoated tablets , debossed \u2018 \u2019 break line one side \u2018 08 \u2019 side . ndc 50268-363-15 ( 10 tablets per card , 5 cards per carton ) glycopyrrolate tablets usp , 2 mg white off-white , round , beveled edge uncoated tablets , debossed \u2018 \u2019 break line one side \u2018 51 \u2019 side . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispensed unit dose packaging . institutional . keep medication reach children . dispense tight container .",
    "adverseReactions": "glycopyrrolate tablets contraindicated : \u2022 patients risk anticholinergic toxicity due underlying medical condition , including : \u2022 glaucoma [ ( 5.1 ) ] \u2022 obstructive uropathies , including prostatic hypertrophy \u2022 mechanical obstructive diseases gastrointestinal tract ( e.g . , pyloroduodenal stenosis , strictures ) [ ( 5.2 ) ] \u2022 gastrointestinal motility disorders ( e.g . , achalasia , paralytic ileus , intestinal atony ) [ ( 5.3 ) ] \u2022 bleeding gastrointestinal ulcer \u2022 active inflammatory infectious colitis lead toxic megacolon \u2022 history current toxic megacolon myasthenia gravis \u2022 patients hypersensitivity glycopyrrolate inactive ingredients glycopyrrolate tablets [ ( 6 ) description ( 11 ) ] .",
    "indications_original": "Glycopyrrolate tablets are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.\n                  \n                  Limitations of Use\n  \nGlycopyrrolate tablets are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.",
    "contraindications_original": "2.1 Important Dosing Information\n  \n\u2022 Glycopyrrolate tablets 2 mg are not recommended for patients in whom a lower dosage strength of oral glycopyrrolate (e.g., glycopyrrolate tablets 1 mg or another 1 mg tablet strength) is appropriate for initial or maintenance treatment because the dosage strength of glycopyrrolate tablets may exceed the recommended initial and maintenance dosage of oral\n  \nglycopyrrolate tablets.\n \n                  \n                  2.2 Recommended Dosage\n  \n\u2022 The recommended initial dosage of glycopyrrolate tablets 1 mg for adults is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate.\n  \n\u2022 The recommended dosage of glycopyrrolate tablets 2 mg for adults is 2 mg two or three times daily at equally spaced intervals.\n  \n\u2022 The maximum recommended daily dosage of glycopyrrolate is 8 mg.\n  \n\u2022 Use the lowest effective dosage of glycopyrrolate to control symptoms. If patients can be titrated to a lower dose, switch from glycopyrrolate tablets 2 mg to glycopyrrolate tablets 1 mg or another 1 mg oral tablet of glycopyrrolate.",
    "warningsAndPrecautions_original": "Glycopyrrolate tablets USP, 1 mg are white to off-white, round, beveled edge uncoated tablets, debossed with \u2018Y\u2019 and break line on one side and \u201808\u2019 on the other side.\n  \nNDC 50268-363-15 (10 tablets per card, 5 cards per carton)\n \n                  \n                  Glycopyrrolate tablets USP, 2 mg are white to off-white, round, beveled edge uncoated tablets, debossed with \u2018Y\u2019 and break line on one side and \u201851\u2019 on the other side.\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled Room Temperature].\n  \nDispensed in Unit Dose Packaging. For institutional Use Only. Keep this and all medication out of the reach of children.\n  \nDispense in a tight container.",
    "adverseReactions_original": "Glycopyrrolate tablets are contraindicated in:\n  \n\u2022 Patients at risk for anticholinergic toxicity due to an underlying medical condition, including:\n  \n\u2022 Glaucoma [see Warnings and Precautions (5.1)]\n  \n\u2022 Obstructive uropathies, including prostatic hypertrophy\n  \n\u2022 Mechanical obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis, strictures) [see Warnings and Precautions (5.2)]\n  \n\u2022 Gastrointestinal motility disorders (e.g., achalasia, paralytic ileus, intestinal atony) [see Warnings and Precautions (5.3)]\n  \n\u2022 Bleeding gastrointestinal ulcer\n  \n\u2022 Active inflammatory or infectious colitis which can lead to toxic megacolon\n  \n\u2022 History of or current toxic megacolon or Myasthenia gravis\n  \n\u2022 Patients with a hypersensitivity to glycopyrrolate or any of the inactive ingredients in glycopyrrolate tablets [see Adverse Reactions (6) and Description (11)].",
    "drug": [
        {
            "name": "Glycopyrrolate",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00986"
        }
    ]
}